JARDIANCE (empagliflozin)


Drug overview for JARDIANCE (empagliflozin):

Generic name: EMPAGLIFLOZIN (EM-pa-gli-FLOE-zin)
Drug class: Antihyperglycemic-Sod/Gluc Cotransport-2 (SGLT2) Inhibitors
Therapeutic class: Endocrine

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is an antidiabetic agent.

No enhanced Uses information available for this drug.
DRUG IMAGES
  • JARDIANCE 10 MG TABLET
    JARDIANCE 10 MG TABLET
  • JARDIANCE 25 MG TABLET
    JARDIANCE 25 MG TABLET
The following indications for JARDIANCE (empagliflozin) have been approved by the FDA:

Indications:
Cardiovascular disease associated with type 2 diabetes mellitus
Chronic heart failure
Kidney disease with reduction in glomerular filtration rate (GFR)
Type 2 diabetes mellitus


Professional Synonyms:
Adult onset diabetes mellitus
Adult onset diabetes
Adult onset DM
Congestive heart failure
Decreased renal function
Diabetes mellitus type 2
Diabetes mellitus type II
Ketosis-resistant diabetes mellitus
Ketosis-resistant DM
Maturity onset diabetes mellitus
Maturity onset diabetes
Nephropathy with reduction in kidney function
Nephrosis with reduction in kidney function
Non-insulin dependent diabetes mellitus
Non-insulin-dependent diabetes mellitus
Renal disorder with reduction in glomerular filtration rate (GFR)
Renal dysfunction
Renal function impairment
Renal impairment
Renal insufficiency
Type II diabetes mellitus